Using Tirzepatide: the decisions that shape your treatment

Is tirzepatide the right tool for your situation?

This is the first decision, and it's not one to make by reading ingredient lists. The UK licence covers adults with a BMI of 30 or above, or 27 and over if there's at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. But meeting those numbers is a starting point, not a guarantee, a prescriber weighs your full medical history, current medicines, and any contraindications before approving treatment.

People who've already tried lifestyle changes without sustained results are often the clearest candidates. So are those who've researched the clinical evidence behind tirzepatide and understand that this is a long-term commitment rather than a short course. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average weight reductions of around 20–21% at the highest dose over 72 weeks, significant figures, but achieved alongside a reduced-calorie diet and increased activity, not instead of them.

Worth being honest about: tirzepatide isn't licensed for use in pregnancy, breastfeeding, or if you're actively trying to conceive. It isn't appropriate for under-18s. And anyone with a history of medullary thyroid carcinoma or certain gastrointestinal conditions needs a thorough prescriber conversation before starting.

What does using tirzepatide week by week actually feel like?

The first pen contains 2.5 mg doses, not because 2.5 mg is where the weight-loss effect lives, but because your body needs time to adjust. Most people notice a reduction in appetite within the first week or two, even at the starter dose. The GI side effects (nausea, occasional loose stools, burping, a feeling of fullness that arrives faster than you're used to) are most pronounced in this early period and after each dose increase. For most people they settle within days to a fortnight.

Injection technique matters more than people expect. Rotating sites between the abdomen, thigh, and upper arm keeps the skin healthy and absorption consistent. Changing the needle on every single use isn't optional; it protects both the pen mechanism and the injection site. If you want to get the most out of every step of treatment, our tips for using Mounjaro cover technique and storage in detail.

Storage is refrigerated at 2–8 °C for unused pens. Once you're using a pen, there's a limited window for room-temperature storage, the exact duration is in the Patient Information Leaflet, and that's the right place to check it rather than relying on memory. One practical note: if you're unsure about anything from your first injection onwards, our guide to using Mounjaro walks through the process clearly, including what to do if a bank holiday or a Monday-to-Friday ordering cut-off falls around the time you'd usually reorder, so you're not caught short between doses.

Managing a dose increase, and knowing when to pause

The decision to step up the dose belongs to your prescriber, not to you alone. NICE's appraisal of tirzepatide (TA1026) and the licensed titration schedule both follow a roughly four-weekly pattern, but that's a framework, not a rule that overrides how you're tolerating the current level. If nausea at 5 mg is still significant at the four-week mark, staying there longer is a reasonable clinical choice.

A good reason to contact your prescriber or care team promptly: severe, persistent abdominal pain that radiates toward the back, especially with vomiting. The MHRA has highlighted acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, that symptom pattern needs same-day medical attention, not a wait-and-see approach. Gallbladder symptoms, signs of dehydration from persistent vomiting or diarrhoea, and any allergic reaction also warrant urgent contact rather than self-management.

Side effects can be reported directly to the MHRA via the Yellow Card scheme, patients can do this themselves, not just clinicians. It's a genuinely useful system, and reporting helps the regulator build a clearer picture of how these medicines perform in real-world use.

Stopping, switching, or continuing: how do you decide?

Not everyone stays on tirzepatide indefinitely, and not everyone should. NICE's guidance suggests reviewing continuation if someone hasn't lost at least 5% of their body weight after six months at the highest tolerated dose. That's a clinical benchmark worth knowing, though the conversation about what comes next (whether that's continuing, switching, or stopping gradually) involves your prescriber and your own goals.

Some people switch from another GLP-1 medicine. If you're transferring to tirzepatide from semaglutide, a regulated pharmacy will ask for evidence of your current treatment and dose, that's not bureaucracy for its own sake, it's how a responsible prescriber avoids starting you at the wrong place. The Mounjaro overview covers the full licensed context if you're still comparing options.

Cost is a real factor in these decisions. Tirzepatide is a private prescription in most cases; the Lilly price increase that took effect in September 2025 changed the market significantly, and understanding what a quoted price includes (or doesn't) is part of planning treatment sustainably. At nume, there's one price that covers the consultation, the prescription, the medicine, and tracked next-working-day delivery. No subscription, no automatic renewal. If you'd like a clinician to look at your situation properly, speak to our prescribers through a free consultation.